Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Shingrix safe in post-transplant patients

Source: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2

Key clinical point: The adjuvanted herpes zoster vaccine met its efficacy endpoint in myeloma patients after transplant.

Major finding: Efficacy was 68.17% for preventing herpes zoster among HSCT recipients.

Study details: A randomized, observer blind, placebo-controlled phase 3 study of 1,846 post-HSCT recipients.

Disclosures: The study was sponsored by GlaxoSmithKline. Dr. de la Serna reported relationships with multiple pharmaceutical companies.

Source: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2.

Citation:

Source: de la Serna J et al. 2018 BMT Tandem Meetings, Abstract LBA2